Perrigo Return on Tangible Equity 2010-2023 | PRGO
Current and historical return on tangible equity values for Perrigo (PRGO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Perrigo Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2023-12-31 | $-0.01B | $-1.75B | 0.72% |
| 2023-09-30 | $-0.01B | $-1.76B | 0.27% |
| 2023-06-30 | $-0.07B | $-1.84B | 3.59% |
| 2023-03-31 | $-0.14B | $-1.90B | 7.34% |
| 2022-12-31 | $-0.14B | $-1.94B | 9.81% |
| 2022-09-30 | $-0.11B | $-1.89B | 11.24% |
| 2022-06-30 | $-0.12B | $-1.96B | 23.67% |
| 2022-03-31 | $-0.11B | $0.08B | -337.98% |
| 2021-12-31 | $-0.07B | $0.00B | -148.39% |
| 2021-09-30 | $-0.25B | $-0.08B | -396.88% |
| 2021-06-30 | $-0.35B | $0.13B | 236.49% |
| 2021-03-31 | $-0.23B | $0.13B | 53.07% |
| 2020-12-31 | $-0.16B | $0.07B | 20.96% |
| 2020-09-30 | $-0.01B | $-0.93B | 0.62% |
| 2020-06-30 | $0.24B | $-1.02B | -19.34% |
| 2020-03-31 | $0.19B | $-1.24B | -15.45% |
| 2019-12-31 | $0.15B | $-1.30B | -12.46% |
| 2019-09-30 | $0.25B | $-1.41B | -21.46% |
| 2019-06-30 | $0.09B | $-0.92B | -7.68% |
| 2019-03-31 | $0.11B | $-1.06B | -9.10% |
| 2018-12-31 | $0.13B | $-1.22B | -9.87% |
| 2018-09-30 | $0.12B | $-1.34B | -8.91% |
| 2018-06-30 | $0.24B | $-1.40B | -16.50% |
| 2018-03-31 | $0.13B | $-1.35B | -8.83% |
| 2017-12-31 | $0.12B | $-1.39B | -8.08% |
| 2017-09-30 | $-1.31B | $-1.56B | 61.66% |
| 2017-06-30 | $-2.95B | $-1.55B | 102.51% |
| 2017-03-31 | $-3.41B | $-1.45B | 91.21% |
| 2016-12-31 | $-4.01B | $-3.95B | 84.24% |
| 2016-09-30 | $-2.83B | $-4.55B | 55.59% |
| 2016-06-30 | $-0.98B | $-5.01B | 18.85% |
| 2016-03-31 | $-0.46B | $-5.54B | 9.11% |
| 2015-12-31 | $0.04B | $-5.25B | -1.13% |
| 2015-09-30 | $0.29B | $-4.91B | -11.04% |
| 2015-06-30 | $0.12B | $-4.68B | -7.02% |
| 2014-12-31 | $0.21B | $-0.40B | -15.86% |
| 2014-09-30 | $0.06B | $-1.46B | -3.33% |
| 2013-12-31 | $0.14B | $-1.98B | -32.66% |
| 2013-09-30 | $0.33B | $0.14B | 219.33% |
| 2012-12-31 | $0.33B | $0.30B | 107.19% |
| 2012-09-30 | $0.32B | $0.43B | 129.58% |
| 2011-12-31 | $0.26B | $0.07B | 185.66% |
| 2011-09-30 | $0.25B | $-0.04B | 172.32% |
| 2010-12-31 | $0.23B | $0.09B | 175.88% |
| 2010-09-30 | $0.20B | $-0.01B | 84.73% |
| 2009-12-31 | $0.16B | $0.51B | 35.29% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $4.066B | $4.656B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $181.079B | 23.71 |
| Stryker (SYK) | United States | $127.496B | 30.54 |
| Medtronic (MDT) | Ireland | $114.087B | 16.15 |
| Boston Scientific (BSX) | United States | $109.519B | 34.88 |
| EssilorLuxottica (ESLOY) | France | $102.905B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.259B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.858B | 28.37 |
| ResMed (RMD) | United States | $32.109B | 30.15 |
| Koninklijke Philips (PHG) | Netherlands | $25.984B | 20.13 |
| Terumo (TRUMY) | Japan | $25.953B | 36.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.724B | 15.79 |
| Baxter (BAX) | United States | $17.963B | 12.77 |
| Insulet (PODD) | United States | $13.116B | 58.16 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.406B | 0.00 |
| Demant (WILYY) | Denmark | $10.234B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.382B | 27.41 |
| BellRing Brands (BRBR) | United States | $7.488B | 35.22 |
| Lantheus Holdings (LNTH) | United States | $5.522B | 13.76 |
| Haemonetics (HAE) | United States | $4.862B | 24.05 |
| GN Store Nord (GNNDY) | Denmark | $4.400B | 24.71 |
| Prestige Consumer Healthcare (PBH) | United States | $3.227B | 15.36 |
| Envista Holdings (NVST) | United States | $3.185B | 13.14 |
| Neogen (NEOG) | United States | $2.933B | 28.21 |
| QuidelOrtho (QDEL) | United States | $2.868B | 15.92 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.846B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.735B | 54.17 |
| TG Therapeutics (TGTX) | United States | $2.547B | 71.65 |
| ICU Medical (ICUI) | United States | $2.534B | 22.36 |
| Agios Pharmaceuticals (AGIO) | United States | $1.950B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.790B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.761B | 51.61 |
| Warby Parker (WRBY) | United States | $1.639B | 0.00 |
| InMode (INMD) | Israel | $1.550B | 8.24 |
| Owens & Minor (OMI) | United States | $1.424B | 12.41 |
| AdaptHealth (AHCO) | United States | $1.329B | 9.88 |
| National Vision Holdings (EYE) | United States | $1.240B | 39.45 |
| AtriCure (ATRC) | United States | $1.101B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.011B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.913B | 0.00 |
| Evolus (EOLS) | United States | $0.851B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.747B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.745B | 15.86 |
| Quanterix (QTRX) | United States | $0.664B | 0.00 |
| Valneva SE (VALN) | France | $0.618B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.612B | 14.39 |
| PetIQ (PETQ) | United States | $0.588B | 19.20 |
| TerrAscend (TSNDF) | Canada | $0.519B | 0.00 |
| Surmodics (SRDX) | United States | $0.494B | 30.91 |
| Jin Medical (ZJYL) | China | $0.465B | 0.00 |
| ZimVie (ZIMV) | United States | $0.464B | 39.58 |
| Aurora Cannabis (ACB) | Canada | $0.403B | 0.00 |
| Cerus (CERS) | United States | $0.364B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.364B | 11.71 |
| Biote (BTMD) | United States | $0.357B | 8.21 |
| Zynex (ZYXI) | United States | $0.346B | 47.30 |
| Viemed Healthcare (VMD) | United States | $0.276B | 27.35 |
| MacroGenics (MGNX) | United States | $0.273B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.264B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.263B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.246B | 15.49 |
| Organigram Holdings (OGI) | Canada | $0.209B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.209B | 0.00 |
| Omeros (OMER) | United States | $0.200B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.197B | 0.00 |
| Veru (VERU) | United States | $0.193B | 0.00 |
| High Tide (HITI) | Canada | $0.175B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.171B | 82.00 |
| InterCure (INCR) | Israel | $0.150B | 25.31 |
| Jushi Holdings (JUSHF) | United States | $0.138B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.134B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.128B | 18.14 |
| Cellectar Biosciences (CLRB) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 8.28 |
| MariMed (MRMD) | United States | $0.094B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Brainsway (BWAY) | Israel | $0.090B | 0.00 |
| Chimerix (CMRX) | United States | $0.089B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.085B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.075B | 0.00 |
| Safety Shot (SHOT) | United States | $0.072B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.062B | 4.03 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.054B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| Bright Green (BGXX) | United States | $0.044B | 0.00 |
| United-Guardian (UG) | United States | $0.043B | 15.45 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Exagen (XGN) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.025B | 0.00 |
| Agape ATP (ATPC) | $0.020B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.014B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.003B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |